Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 8/31/2025

Temporal Arteritis Diagnosis and Treatment

Clinical Presentation

  • The American College of Rheumatology suggests that temporal arteritis presents with new-onset persistent localized headache, often in the temporal area, scalp tenderness, and constitutional symptoms, requiring immediate high-dose glucocorticoid therapy to prevent permanent vision loss 1, 2
  • Jaw and/or tongue claudication is a highly specific symptom with a positive likelihood ratio (LR) of 4.90 3, 4
  • Temporal artery tenderness and/or thickening with or without reduced pulsation has a positive LR of 3.14-4.70 1, 2, 4

Diagnostic Approach

  • Patients with suspected giant cell arteritis (GCA) should be referred urgently for diagnostic work-up, with fast-track referral within 24 hours to reduce the rate of permanent visual impairment 1, 2
  • Temporal artery biopsy with specimen length >1 cm is recommended for confirmatory testing 5, 7
  • Vascular imaging (ultrasound, MRI, PET, CT) can identify large vessel involvement 5, 6

Treatment Approach

  • High-dose glucocorticoid therapy (40–60 mg/day prednisone-equivalent) should be initiated immediately to prevent permanent vision loss 1, 2
  • Once disease is controlled, taper glucocorticoid dose to 15–20 mg/day within 2–3 months, and target dose should be ≤5 mg/day after 1 year 1, 2
  • Tocilizumab has demonstrated efficacy in reducing glucocorticoid requirements and flare rates 5, 8

Laboratory Findings

  • Elevated erythrocyte sedimentation rate (ESR) and/or C-reactive protein (CRP) is found in >95% of cases, with ESR >100 mm/h having a positive LR of 3.11 3, 4, 5, 6
  • Platelet count >400 × 10³/μL has a positive LR of 3.75, while absence of CRP ≥2.5 mg/dL has a negative LR of 0.38 3, 4

Monitoring

  • Regular assessment for clinical signs and symptoms of active disease, monitoring inflammation markers (ESR, CRP), and assessing for glucocorticoid-related adverse effects are essential for patient management 7, 8